
Aditxt, Inc. — Investor Relations & Filings
Aditxt, Inc. is an innovation company focused on acquiring, developing, and deploying promising health technologies. Its business model involves acquiring disruptive and scalable companies, leveraging its business acceleration platform to drive growth, and monetizing assets through various strategies including mergers, sales, and licenses. The company's portfolio of programs targets significant health challenges. Current programs include Adimune, focused on autoimmunity; Pearsanta, for early cancer detection; and Adivue, for neurological diagnostics. Aditxt also has planned programs and proposed acquisitions in areas such as reproductive health.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K - Aditxt, Inc. (0001726711) (Filer) | 2026-04-14 | English | |
| S-3 - Aditxt, Inc. (0001726711) (Filer) | 2026-04-11 | English | |
| 8-K/A - Aditxt, Inc. (0001726711) (Filer) | 2026-04-07 | English | |
| DEF 14A - Aditxt, Inc. (0001726711) (Filer) | 2026-04-03 | English | |
| 8-K - Aditxt, Inc. (0001726711) (Filer) | 2026-04-02 | English | |
| 8-K - Aditxt, Inc. (0001726711) (Filer) | 2026-03-30 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
11 filings
| |||||
| 34484140 | 8-K - Aditxt, Inc. (0001726711) (Filer) | 2026-04-14 | English | ||
| 34402623 | S-3 - Aditxt, Inc. (0001726711) (Filer) | 2026-04-11 | English | ||
| 33743863 | 8-K/A - Aditxt, Inc. (0001726711) (Filer) | 2026-04-07 | English | ||
| 33302978 | DEF 14A - Aditxt, Inc. (0001726711) (Filer) | 2026-04-03 | English | ||
| 33158825 | 8-K - Aditxt, Inc. (0001726711) (Filer) | 2026-04-02 | English | ||
| 33087919 | 8-K - Aditxt, Inc. (0001726711) (Filer) | 2026-03-30 | English | ||
| 33066090 | 424B5 - Aditxt, Inc. (0001726711) (Filer) | 2026-03-27 | English | ||
| 31498298 | 8-K Filing | 2026-02-13 | English | ||
| 31498392 | 8-K Filing | 2026-01-30 | English | ||
| 31498344 | SCHEDULE 13G Filing | 2026-01-30 | English | ||
| 31498281 | 8-K Filing | 2026-01-28 | English | ||
|
2025
4 filings
| |||||
| 13087095 | Director's Dealing 2025 | 2025-12-19 | English | ||
| 13087096 | DEFINITIVE PROXY STATEMENT | 2025-12-16 | English | ||
| 13087097 | PROSPECTUS SUPPLEMENT | 2025-12-12 | English | ||
| 13087099 | REVISED PRELIMINARY PROXY STATEMENT | 2025-12-05 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
BetterLife Pharma
Developing non-hallucinogenic neuroplastogens for severe ne…
|
BETR | CA | Professional, scientific and te… |
|
BGI Genomics Co., Ltd.
Provides integrated solutions for precision medicine via ge…
|
300676 | CN | Professional, scientific and te… |
|
bioAffinity Technologies, Inc.
Develops noninvasive diagnostics and targeted therapeutics …
|
BIAF | US | Professional, scientific and te… |
|
BioArctic
Biopharmaceutical firm developing antibody therapies for ne…
|
BIOA | SE | Professional, scientific and te… |
|
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Develops antibody therapeutics using proprietary RenMice ge…
|
688796 | CN | Professional, scientific and te… |
|
BIO-GENE TECHNOLOGY LTD
Develops novel insecticides from natural chemistry to comba…
|
BGT | AU | Professional, scientific and te… |
|
BioInfra Co.,Ltd.
Develops multi-biomarker blood tests for early cancer scree…
|
199730 | KR | Professional, scientific and te… |
|
BioInfra Life Science Inc.
Develops multi-biomarker blood tests for early cancer scree…
|
266470 | KR | Professional, scientific and te… |
|
Biomark Diagnostics Inc.
Oncology liquid biopsy diagnostics using metabolomics and A…
|
BUX | CA | Professional, scientific and te… |
|
Biomind Labs
Developing novel pharmaceutical drugs for patients with neu…
|
BMND | CA | Professional, scientific and te… |
Aditxt, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/35447/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=35447 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=35447 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=35447 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 35447}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Aditxt, Inc. (id: 35447)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.